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https://doi.org/10.1186/s40478-018-0572-7RESEARCH Open AccessE90 subunit vaccine protects mice from
Zika virus infection and microcephaly
Xingliang Zhu1,2†, Chunfeng Li3,4,5†, Shabbir Khan Afridi1,2†, Shulong Zu2,6†, Jesse W. Xu5, Natalie Quanquin7,
Heng Yang3,4, Genhong Cheng3,4,7* and Zhiheng Xu1,2,8*Abstract
Zika virus (ZIKV) became a global threat due to its unprecedented outbreak and its association with congenital
malformations such as microcephaly in developing fetuses and neonates. There are currently no effective vaccines
or drugs available for the prevention or treatment of ZIKV infection. Although multiple vaccine platforms have been
established, their effectiveness in preventing congenital microcephaly has not been addressed. Herein, we tested a
subunit vaccine containing the 450 amino acids at the N-terminus of the ZIKV envelope protein (E90) in mouse
models for either in utero or neonatal ZIKV infection. In one model, embryos of vaccinated dams were challenged
with a contemporary ZIKV strain at embryonic day 13.5. The other model infects neonatal mice from vaccinated
dams by direct injection of ZIKV into the developing brains. The vaccine led to a substantial reduction of ZIKV-
infected cells measured in the brains of fetal or suckling mice, and successfully prevented the onset of
microcephaly compared to unvaccinated controls. Furthermore, E90 could protect mice from ZIKV infection even at
140 days post-immunization. This work directly demonstrates that immunization of pregnant mice protects the
developing brains of offspring both in utero and in the neonatal period from subsequent ZIKV infection and
microcephaly. It also supports the further development of the E90 subunit vaccine towards clinical trials.
Keywords: Zika virus, E90 vaccine, Protection, Microcephaly, Mouse modelIntroduction
Zika virus (ZIKV) belongs to the Flaviviridae family, and
was first isolated from a sentinel monkey in the Zika forest
of Uganda in 1947 [10]. Only sporadic human infections
were reported in Africa and Asia until 2007, when the first
ZIKV outbreak was documented on the Yap Island of
Micronesia [26]. Like most other flaviviruses, ZIKV is pre-
dominantly spread by female Aedes spp. mosquitoes [23].
However, there is evidence that ZIKV can also be spread
by mother-to-child vertical transmission [4, 24], sexual
activity [14], and blood transfusion [25]. Prior to 2010,
only benign symptoms were reported in ZIKV patients,
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(http://creativecommons.org/publicdomain/zearthralgia, with 80% of cases being completely asymptom-
atic. However, during the recent outbreak in the Americas
and the Caribbean, more severe clinical outcomes began
to emerge [12]. Investigations using both human samples
and animal models showed that ZIKV not only induces a
series of immunological reactions [23, 29], but also infects
neuronal progenitor cells (NPCs), potentially causing con-
genital microcephaly [6, 21, 23] or fetal demise [24].
Currently, a large number of anti-ZIKV therapeutics are
being developed. Many of these candidates have been
shown to be effective both in vitro and in vivo, including
25-hydroxycholesterol and chloroquine, and drugs such as
Sofosbuvir, BCX4450, NITD008 and 7-DMA are entering
phase I clinical trials [2, 20, 22, 36]. Another approach is
immune-based therapy. Antibodies targeting specific ZIKV
components have been shown to be able to prevent ZIKV
infection in vivo [7, 37, 41]. Interferon therapy has also
been tested, but is controversial due to conflicting results
in different cell systems [15].
Compared to the above methods, vaccination is consid-
ered a potentially safer and more effective approach tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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using different platforms and targets have also advanced
into phase I clinical trials [3, 11, 31]. However, none of
these candidates have been tested for their ability to pro-
tect the fetus or infants born to infected mothers, espe-
cially from devastating sequelae such as microcephaly.
Han et al. showed that co-administration of ZIKV and sera
from mice immunized with a ZIKV envelope protein sub-
unit vaccine (E90) reduced the lethality of the infection,
protecting neonates from death [16]. However, we sought
to directly explore the potential of this vaccine to confer
protection from pregnant dams to offspring in utero and
reduce ZIKV-associated complications.
Given the life-long disabilities that may result from
microcephaly, including cognitive and motor deficits,
it is critically important that we continue to explore
effective anti-ZIKV strategies. Herein, we investigated
the protective effects of the E90 vaccine against ZIKV
using both prenatal and neonatal mouse models. We
successfully demonstrated that maternal immunization
with E90 protected offspring from ZIKV challenge and
microcephaly both in utero and in the neonatal period
compared to placebo controls. Moreover, about
140 days after the first immunization, the immunized
mice still carried significant titers of anti-ZIKV IgG
that protected them from an otherwise lethal challenge
with the virus.
Materials and methods
Detailed methods are provided as follows:
 MOUSE EXPERIMENTS
ICR mice were purchased from Beijing Vital River
Laboratory Animal Technology Co., Ltd.. All animals were
bred in our core animal facility. After infections with ZIKV,
all animals were housed in the P2 biosafety laboratory.
For immunizations, female mice were inoculated i.p. with
about 100 μl of E90 (50 μg/mouse) or PBS (as a placebo)
with the antigen adjuvant AddaVax™ (50 μl/mouse). The
mice were boosted with the same dose of vaccine 14 days
after the first immunization, and were bled 2 weeks later
for serological analysis. Later, dams were mated to sires of
the same age. One batch was used to perform in utero
experiments, and the other was allowed to give birth, with
neonates then used for further experiments.
For the prenatal microcephaly model, approximately 1 μl
of ZIKV virus stock (600 PFU/mouse) or culture medium
was injected into the cerebral lateral ventricle of E13.5 CD
(ICR) mouse brains and inspected after 5 days as described
previously. For each pregnant dam, 1/3 to 1/2 of the litter-
mates were injected. In the postnatal model, around 100
PFU/mouse or culture medium was injected into the middle
zone between the bregma point and lambda point ofsuckling mice at P1 or P2. The mice were weighed every
other day and were sacrificed and inspected at P10.
 METHOD DETAILS
 Viruses
ZIKV strains (GZ01, GenBank: KU820898 or
FSS13025, Genbank: JN860885) used in this study were
described in our previous work [9, 22].
 Generation of protein subunit vaccine
ZIKV recombinant E90 protein was produced as de-
scribed previously [16]. Briefly, the gene fragment en-
coding the first 450 amino acids of the E protein from
ZIKV strain FSS13025 was cloned into the pET28a vec-
tor, and then expressed in Escherichia coli BL21 (DE3).
The recombinant protein was purified by Ni-NTA agar-
ose, and was checked by SDS-PAGE and confirmed by
Western blot using mouse anti-flavivirus antibody 4G2.
The concentration of purified E90 protein was measured
using the BCA protein assay kit.
 ELISA
Purified recombinant ZIKV E protein [7] (100 ng/well)
was coated on ELISA plates at 4 °C for overnight. Serum
from CD1 mice was serially diluted with PBS containing
1% BSA and added to the E protein-coated plate for 1 h
at 37 °C. The plate was then washed with PBST and in-
cubated with HRP-conjugated IgG for 1 h at 37 °C. After
washing with PBST, the plate was incubated with TMB
solution before adding stop solution. The OD450 was
measured with a microplate reader, and the samples
were defined as positive by an OD450 two times higher
than the background.
 RNA isolation and qRT-PCR
Total RNA from serum was extracted with the EasyPure
Viral DNA/RNA Kit (TransGen Biotech, Beijing). ZIKV cop-
ies were measured by real-time quantitative PCR (qRT-PCR)
[18]. ZIKV primers were described previously [8].
 Plaque reduction neutralization test (PRNT)
The neutralizing antibody titers in serum were deter-
mined in BHK-21 cells via PRNT as described [1]. Briefly,
the serial dilutions of serum in PBS were mixed with ZIKV
and incubated at 37 °C for 1 h. The above mixture was then
added to BHK-21 cells and incubated for 1 h at 37 °C
before adding overlay media mixed with agar. Plaques were
counted after 4 days, with the average number in the
control group set as 0, representing no neutralization.
Zhu et al. Acta Neuropathologica Communications  (2018) 6:77 Page 3 of 12 Histology and immunohistochemistry
Brains were harvested at E18.5 and P10, then were fixed
in 4% PFA. After 24 h, the brain tissues were dehydrated
in 30% sucrose, and frozen in TFM (tissue freezing
medium) for cryosections after another 24 h. Sections
(thickness: 40 μm) were immunostained as described pre-
viously [22]. Briefly, sections were blocked at RT for 1 h,
incubated with the first antibody at 4 °C overnight, washed
3 times with PBST, then incubated with the secondary
antibody at RT for 1 h, followed by 3 washes. The anti-
bodies used for immunostaining are listed in the
Additional file 1: Table S1. Slices were imaged on a LSM
700 (Carl Zeiss) confocal microscope (10×/0.3, 20×/0.5,
25 °C, in air medium) using ZEN software. For Nissl
staining, brain slices were stained with 0.1% toluidine blue
for 15 min, dehydrated serially in 70, 96, and 99% ethanol
(45 s twice each). Finally, slices were hyalinized by Xylene
for 5 min before sealing with neutral balsam.
 QUALIFICATION AND STATISTICAL ANALYSIS
Images were qualified with ZEN (Blue edition), ImageJ or
Imaris as described previously [22]. All data were analyzed
by GraphPad software. Statistical evaluations were per-
formed by Student’s unpaired t-test. Data were presented as
the mean ± standard error of the mean (*p ≤ 0.05, **p ≤
0.01, ***p ≤ 0.001). Survival curves were analyzed by the
log-rank (Mantel-Cox) test. All the representative images
shown in the paper were from at least three independent
experiments.
 ADDITIONAL RESOURCES
E90 and purified recombinant ZIKV E protein are kind
gifts from Dr. Cheng-Feng Qin at the Beijing Institute of
Microbiology and Epidemiology.
 SUPPLEMENTAL INFORMATION
The reagents and primers used in this paper are listed
in the supplementary table.
Results
ZIKV E protein-based vaccine E90 protects adult mice
from ZIKV infection
The E90 subunit vaccine is composed of the first 450
amino acids of the ZIKV FSS13025 strain envelope (E)
protein [16], representing 90% of the coding sequence and
excluding the C-terminal transmembrane domain. E90’s
amino acid sequence is fairly conserved, sharing about
99.8% similarity with other ZIKV strains. The gene seg-
ment was expressed in Escherichia coli and purified as de-
scribed previously [16]. 7–8 week-old female CD-1 (ICR)immunocompetent mice were divided into three groups.
One group was inoculated with E90 (50 μg/mouse) and
the adjuvant AddaVax™ (50 μl/mouse) by the intraperito-
neal route (i.p.). The other two groups were injected i.p.
with PBS and the same quantity of adjuvant. The mice
were given a single boost two weeks later. 14 and 28 days
following the first immunization, serum was collected for
ELISA assay and standard plaque reduction neutralization
testing (PRNT). A selection of mice from the immunized
group and one placebo group were infected with the ZIKV
GZ01 strain (105 PFU/mouse) via the i.p. route, and their
viremia was measured at 1 day post-infection (dpi).
As shown in Fig. 1a-b, the specific anti-ZIKV IgG titer was
as high as 104 in the E90-immunized mice, with the PRNT50
titer from serum measured as 1:70, reflecting high titers of
ZIKV-neutralizing antibodies. By contrast, mice vaccinated
with PBS developed no detectable ZIKV-neutralizing anti-
bodies or ZIKV-specific IgG (Fig. 1a-b). Consistent with
these results, a significantly reduced viral burden was noted
in the E90-vaccinated group compared to control mice after
ZIKV challenge (Fig. 1c). Together, these results showed that
the E90 subunit vaccine could effectively protect adult mice
from ZIKV infection.
E90 vaccine protects embryonic brains from ZIKV-induced
microcephaly
We then evaluated the efficacy of this vaccine in protect-
ing the offspring of pregnant mice from ZIKV infection,
utilizing the same microcephaly model developed previ-
ously [21, 22, 39]. In this model, dams were given E90 or
PBS as described above and mated at D28 (Fig. 1d). About
1 μl (600 PFU) of ZIKV or culture medium was injected
into the lateral ventricle of fetal brains in utero at embry-
onic day 13.5 (E13.5) (Fig. 1e), as described previously
[21]. Brain samples were inspected at E18.5. As shown in
Fig. 2a, the average brain size of the vaccinated group was
significantly larger than that of the placebo group. Like-
wise, the brain cortices of vaccinated mice remained much
thicker after infection than those of infected unvaccinated
mice (Fig. 2a). In addition, Nissl staining showed that indi-
vidual cortical layers in the ZIKV-infected placebo group
were significantly thinner than those in the mock and vac-
cinated groups (Fig. 2b). Furthermore, we inspected ZIKV
density in embryonic brains via immunostaining, and
found that the number of infected cells was considerably
decreased in the vaccinated group compared to control
mice (Fig. 3a). Similarly, the relative level of apoptosis
(marked by activated caspase3+ cells) was significantly
reduced in the vaccinated group (Fig. 3a).
ZIKV has been shown to infect neural progenitor cells
(NPCs) and affect their proliferation [21, 35]. We therefore
investigated the impact of vaccination on mouse NPCs by
examining their levels of phosphorylated histone H3
(P-H3), a marker for being in the M-phase. We noticed
ad e
b c
Fig. 1 ZIKV E protein-based vaccine E90 prevents ZIKV infection in adult mice: a. ZIKV-specific IgG titers were analyzed at 14 and 28 days post-vaccination
in mice. b. The ZIKV-neutralizing activity of serum from E90-immunized mice (2 weeks after a single boost) was analyzed by standard plaque reduction
neutralization test (PRNT). c. ZIKV copies in serum from E90-immunized CD1 mice 1 day after ZIKV challenge (GZ01 strain, 105 PFU/mouse) were analyzed
by qRT-PCR. PBS, n= 6; E90, n= 5. All data are means ± SEM. Student’s t-test. **p< 0.01. d. Schematic for the immunizations of CD1 (ICR) female mice and
the two models for testing the protection effect in offspring. e. Virus titers used in the prenatal and postnatal models
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mock-infected and infected vaccinated groups, with a re-
duction in infected unvaccinated mice (Fig. 3b). This same
trend was seen when examining cortical cells for expression
of Sox2+ (a NPC marker) and Tbr2+ (a marker for inter-
mediate/basal progenitor cells) (Fig. 3c). In addition, the
levels of Tbr1+ (a maker for immature neurons) and NeuN+
(a marker for mature neurons) cells were also both ob-
served to be decreased in the infected unvaccinated group,
compared to either the vaccinated or the uninfected groups
(Fig. 3d-e). Together, these results demonstrate that E90
vaccination of mothers induces a protective immune re-
sponse that is transmitted to fetuses to neutralize ZIKV,
preventing the virus from replicating and inducing neur-
onal apoptosis or interfering with NPC proliferation, which
could otherwise result in microcephaly.
E90 vaccination of dams protects offspring from ZIKV-
induced microcephaly
Although many infections are more likely to cause
congenital defects when occurring in early stages of fetal
development, cases of microcephaly from maternal ZIKV
infections taking place late in the second trimester or even
early in the third trimester have been reported [5, 17, 28].As the gestation period of mice is relatively short, to simu-
late infections taking place in the later stages of human fetal
development [13, 38], we injected the brains of one-day-old
suckling mice with 100 pfu of ZIKV [40]. These mice were
born to dams vaccinated with E90 or PBS (Fig. 1d), and we
theorized that protective maternal antibodies may still be
circulating or could be absorbed through the breast milk.
The morbidity and mortality of these littermates were mon-
itored. Pups in the placebo group showed significantly re-
duced weight gain in both their body and brain at P10
(9 days after ZIKV infection) compared to uninfected con-
trols, while this effect was less pronounced in the vacci-
nated group (Fig. 4a). In addition, brain cortices of the
neonatal mice in the vaccinated group were significantly
thicker than those of the placebo group (Fig. 4b).
To more closely examine the level of infection in neonatal
mouse brains, we did immunohistochemistry of cortical
slices. We found that compared to the placebo group, the
levels of ZIKV infection and cell death in different brain re-
gions of neonatal mice born to vaccinated mothers were
significantly decreased (Fig. 5a, Additional file 2: Figure S1).
In addition, there was less reduction in mature neurons
(NeuN as a marker) in the infected neonates born to vacci-
nated compared to unvaccinated mothers (Fig. 5b).
ab
Fig. 2 The E90 vaccine protects embryonic brains from ZIKV-induced microcephaly. a. Comparisons of brain sizes and cortex thickness between
mock-infected mice (Mock + Veh), unvaccinated (ZIKV + Veh) and vaccinated (ZIKV + E90) infected groups. Embryonic brains were injected with
ZIKV or medium at E13.5 and inspected at E18.5 as shown in Fig. 1d. Nissl staining of coronal sections is shown in the lower panel. Right panel
shows measured cortex thickness. Mock + Veh: n = 12/4, ZIKV + Veh: n = 9/4, ZIKV + E90: n = 9/3. b. Nissl staining of different cortical layers. Right
panel shows measured thickness of each layer. Mock + Veh: n = 12/4, ZIKV + Veh: n = 9/4, ZIKV + E90: n = 9/3. CP: cortical plate, SP: subplate, IZ:
intermediate zone, SVZ: subventricular zone, VZ: ventricular zone. All data are means ± SEM. Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001;
##p < 0.01, ###p < 0.001. ns: not significant. n: # of slices/# of individual brains. Scale bar = 1 mm (a), 100 μm (b)
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genitors) was significantly higher in the infected vaccinated
group compared to the infected unvaccinated group (Fig.
5c), indicating that gliogenesis was preserved. Interestingly,
activation of microglia (Iba1 as a marker) was noted in both
infected groups, especially in mice born of vaccinated
mothers (Fig. 5d), suggesting that the vaccine may have trig-
gered a stronger immune response in those mice. In an
additional experiment, we selected suckling neonatal mice
born 120 days after dams had been vaccinated with E90 or
PBS and challenged them 2 days later (P2) with a lethal
dose of ZIKV. We noted that 100% of the mice born of im-
munized mothers survived, while there were no survivors in
the placebo group (Fig. 5e). In summary, these results indi-
cate that neonatal mice continue to benefit from the pro-
tective effects of maternal vaccination with E90, showing
reduced destruction of neurons and glial cells caused by
ZIKV infection. In addition, the duration of protection from
the vaccine, as measured by improved survival against lethal
ZIKV challenge in neonatal mice born of vaccinated dams,
extends to at least 120 days.E90 protection from ZIKV infection extends to at least
140 days post-vaccination
To further characterize the protective effects of E90 several
months after vaccination, CD-1 female mice were immu-
nized as above, and serum was collected at day 130 (D130)
post-immunization for ELISA and PRNTassays (Fig. 6a). Im-
munized mice were then treated with anti-Ifnar1 antibody
(2 mg/mouse) at D135 and challenged with ZIKV (GZ01
strain, 105 PFU/mouse) via the i.p. route at D136. Viral loads
in the sera of mouse dams were measured at D140. Two
days later, the mice were sacrificed and viral RNA was iso-
lated from the brains and spleens for measurement by
qRT-PCR. Our results showed that at D130, anti-ZIKV IgG
levels remained as elevated as they were 14 days after
boost (Fig. 6b and Fig. 1a). The PRNT50 was estimated as
1:94 (Fig. 6c). As expected, viremia in vaccinated mice at
D140 was largely reduced compared to unimmunized
mice (Fig. 6d). Consistent with this result, viral loads in
the spleens and brains of unimmunized mice were very
high, while those of E90-vaccinated mice were signifi-
cantly reduced (Fig. 6e-f). These results indicate that E90
ad e
b
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Fig. 3 E90 protects embryonic brains from ZIKV infection, dysregulation of NPC proliferation, and loss of neurons. Mouse dams were vaccinated
and embryos were infected as in Fig. 2. Coronal brain sections were stained with different antibodies as indicated. a. Relative signal intensity by
fluorescent antibodies against ZIKV or the activated form of caspase3 (Casp3). Mock + Veh: n = 6/3, ZIKV + Veh: n = 6/3, ZIKV + E90: n = 7/3. b.
Quantification of P-H3+ cell numbers in the cortices. Mock + Veh: n = 10/4, ZIKV + Veh: n = 8/4, ZIKV + E90: n = 9/3. c. Quantification of Sox2+ and
Tbr2+ cell density. Mock + Veh: n = 10/4 (Sox2+, Tbr2+); ZIKV + Veh: n = 7/3 (Sox2+, Tbr2+); ZIKV + E90: n = 9/3 (Sox2+, Tbr2+). d. Quantification of
Tbr1+ cell density in cortices. Mock + Veh: n = 11/4, ZIKV + Veh: n = 7/4, ZIKV + E90: n = 8/3. e. Quantification of NeuN+ cell density. Mock + Veh:
n = 12/4, ZIKV + Veh: n = 8/4, ZIKV + E90: n = 8/3. All data are means ± SEM. Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001. ns: not significant.
n: # of slices/ # of individual brains. Scale bar = 100 μm (a-e)
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bodies, which can protect immunocompetent mice from
ZIKV infection up to at least 142 days after the first
vaccine dose.
Discussion
After ZIKV was discovered to be a global threat to public
health, researchers began striving to develop effective thera-
peutics and interventions. Several vaccine candidates
employing different strategies are currently undergoing
clinical trials, such as Inovio’s DNA vaccine [11], theNIAID/Butantan pentavalent live-attenuated vaccine (ZIKV
+ DENV), and a ZIKV purified inactivated vaccine (ZPIV,
NIAID/BARDA/WRAIR/Sanofi Pasteur/+Fiocruz) [23, 31,
36]. However, most of these ZIKV vaccine platforms were
not evaluated for protective effects during pregnancy.
Although Richner et al. did look at the effectiveness of the
modified mRNA and the live-attenuated candidates against
in utero transmission of ZIKV in mice [32], they did not
show direct evidence of their protective roles in embryonic
and neonatal brains after ZIKV infection, including
microcephaly-related complications.
ab
Fig. 4 E90 vaccination of dams protects neonates from ZIKV-induced microcephaly. a. Comparison of body weights and brain sizes of mock–
infected and ZIKV-infected vaccinated and unvaccinated groups as shown in Fig. 1d. Neonatal brains were injected with ZIKV or medium at P1
and inspected at P10. Lower panels: measurements of body and brain weights. For body weight, Mock + Veh: n = 15, ZIKV + Veh: n = 15, ZIKV +
E90: n = 10. For brain weight, Mock + Veh: n = 5, ZIKV + Veh: n = 5, ZIKV + E90: n = 4. b. Nissl staining of coronal sections. Right panel: thickness of
the cortical layer. Mock + Veh: n = 12/4, ZIKV + Veh: n = 8/3, ZIKV + E90: n = 11/4. All data are means ± SEM. Student’s t-test. *p < 0.05, **p < 0.01,
***p < 0.001. ns: not significant. n: # of slices/# of individual brains. Scale bar = 1 cm (a), 1 mm (b)
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previous efforts to develop a vaccine for dengue virus
(DENV), a related flavivirus. A peptide derived from the
DENV E protein has been reported to inhibit infection by
DENV types 1–4 and even other flaviviruses, includingCentral European encephalitis virus, Russian Spring-Summer
encephalitis virus and West Nile virus [33]. E protein is a
reasonable vaccine target due to its critical roles in viral
attachment, entry, and replication in the infected host.
Neutralizing antibodies produced in vivo against the E
a b
c
d
e
Fig. 5 E90 vaccination of dams protects neonatal brains from ZIKV infection, cell death and survival. The brains of neonates born to vaccinated or
unvaccinated mice were injected with ZIKV or medium as in Fig. 4. Coronal brain sections were stained with different antibodies as indicated. a.
Relative signal intensity for ZIKV or activated caspase3 (Casp3). Mock + Veh: n = 11/4 (ZIKV), 11/4 (Casp3); ZIKV + Veh: n = 9/4 (ZIKV), 12/4 (Casp3);
ZIKV + E90: n = 11/4 (ZIKV), 11/4 (Casp3). b. Quantification of NeuN+ cell numbers. Mock + Veh: n = 8/4, ZIKV + Veh: n = 8/4, ZIKV + E90: n = 9/4.
c. Quantification of S100β+ cells. Mock + Veh: n = 11/4, ZIKV + Veh: n = 9/4, ZIKV + E90: n = 8/4. d. Quantification of Iba1+ cells. Mock + Veh:
n = 11/4, ZIKV + Veh: n = 9/4, ZIKV + E90: n = 8/4. e. Improved survival rate of ZIKV-infected neonatal mice (P2) in the vaccinated group at
120 days post-vaccination. n = 12 per group, ****p < 0.0001, Log-rank (Mantel-Cox) test. Data (a-d) represent means ± SEM. Student’s t-test.
*p < 0.05, **p < 0.01, ***p < 0.001. ns: not significant. n: # of slices/# of individual brains. Scale bar = 100 μm (a-d)
Zhu et al. Acta Neuropathologica Communications  (2018) 6:77 Page 8 of 12protein work well against other flaviviruses, such as the
Japanese encephalitis, yellow fever, and tick-borne encephal-
itis viruses [30]. In 2016, Larocca et al. developed a prM-Env
DNA vaccine offering complete protection against ZIKV[19]. Diamond et al. demonstrated that an mRNA vaccine
encoding prM-E protected mice from ZIKV infection [32].
Pardi et al. further showed that a prM–E mRNA vaccine
enveloped by lipid-nanoparticles protected non-human
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Fig. 6 Vaccination with E90 protects mice against ZIKV infection for up to 140 days. a. Schematic for the immunizations of CD1 (ICR) female mice
with subsequent testing between day 130 (D130) to day 142 (D142), treatment with anti-Ifanr1 antibody at D135, and ZIKV infection at D136.
Viremia was measured at D140 and viral loads in organs were measured at D142. b-c. The anti-ZIKV titers were quantified by ELISA (b) or PRNT
(c) in mice at D130. d. ZIKV viremia in mice measured at D140. e-f. Levels of ZIKV RNA recovered from the spleens (e) and brains (f) of
ZIKV-infected mice. PBS, n = 4; E90, n = 3 or 4. All data are means ± SEM. Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001
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immunization [27]. In 2017, Han et al. found that E90 anti-
sera from immunized mice could directly neutralize ZIKV
by co-administering the sera and a lethal dose of ZIKV to-
gether i.p. into neonatal mice, who showed improved sur-
vival over infected mice [16]. Our study has expanded upon
this work, demonstrating for the first time that the protective
effects of a ZIKV vaccine in mouse dams can be transmitted
transplacentally to offspring, leading to improved survival
and a reduction in ZIKV burden and impairment of neural
cells after in utero or perinatal ZIKV infection compared to
infected mice born to unvaccinated mothers.
To overcome the shortcomings of existing vaccines and
expand our knowledge of ZIKV-related effects in the em-
bryonic period, we adopted the E90 subunit vaccine plat-
form for use in two mouse microcephaly models. One
model inspects the brain at E18.5 (5 days after ZIKV inocu-
lation), which helps us to investigate the protective effect in
the embryonic period. The other examines the brain at
P10, 9 days following ZIKV infection of neonatal mice,
which we suggest could be comparable to late trimesterinfections in humans. Our study demonstrated the efficacy
of the E90 vaccine in reducing the viral burden and im-
paired development of ZIKV-infected mouse brains in both
models. Additionally, to represent even earlier time points
in development, we infected mice at E6, which we suggest
might be the equivalent to the first trimester in humans.
We found that at E16.5, the viral load in the placenta from
the group whose mothers were vaccinated with E90 was
significantly reduced compared to the PBS group
(Additional file 3: Figure S2a-b). Moreover, there were clear
signs of damage to the fetus in the placebo group at E18.5,
compared to the mice born of vaccinated mothers, who all
delivered normally at E20 (Additional file 3: Figure S2c-d).
We also inspected the safety of this vaccine and found
no obvious adverse effects in mice, including changes in
body weight (Additional file 4: Figure S3). Since this is a
protein-based vaccine, there is no risk of virulence or
concerns for mutant reversion, oncogenic insertions, or
other complications related to live vaccines or nucleic
acid vaccine platforms. Safety is a critical concern for a
ZIKV vaccine, given that both pregnant women and
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tated by this infection, are immunocompromised. Other
safety concerns with live vaccine strains are that they
might be taken up by mosquitos and recombined with
wild-type strains, although Shan et al. specifically tested
their attenuated ZIKV strain and found it was incapable
of infecting mosquitoes [34]. A cost for protein vaccines
being non-infectious and considered relatively safe is
their low immunogenicity, which may require multiple
doses or the use of an adjuvant to stimulate effective
neutralizing antibody titers. After a single boost of E90
combined with the AddaVax™ adjuvant in adult female
mice, we measured the serum anti-ZIKV IgG titer to be
approximately 104, which persisted for at least 116 days
after the boost (Fig. 1a and Fig. 6b). This represents
long-lasting protection against ZIKV infection, which we
demonstrated through reduced viremia and organ bur-
dens in those mice after viral challenge.
Our findings in adult, embryonic and neonatal mice using
the E90 vaccine are promising, however we acknowledge
that the protection was not complete. The ZIKV burden and
neuronal cell death were reduced in vaccinated mice com-
pared to unvaccinated controls, but not completely elimi-
nated. Gliogenesis was also more prevalent in the vaccinated
group, but still reduced compared to uninfected controls.
In conclusion, we were able to demonstrate that the E90
subunit vaccine could confer protection to adult mice against
ZIKV as measured by the reduced viral burden in the brain,
and that this protection was also seen in their offspring using
models of infection at different stages of development. Our
studies demonstrate the importance of testing ZIKV vaccines
in pregnant animal models, and show evidence that this pro-
tection can significantly preserve fetal brain development
and reduce the incidence and extent of microcephaly.Conclusions
We demonstrate the E90 subunit vaccine can protect
adult mice from ZIKV infection. Immunization of preg-
nant dams protects their fetuses and offspring from
ZIKV infection and reduces the risk of microcephaly.
Moreover, the protective effect of E90 against ZIKV is
present even 128 days after the second dose.Additional files
Additional file 1: Supplemental experimental materials. (XLSX 10 kb)
Additional file 2: Figure S1. E90 suppresses ZIKV infection in different
regions of neonatal mouse brains. a-e. Comparisons of ZIKV infection and
apoptosis in mock–infected or ZIKV-infected vaccinated and unvaccin-
ated groups. Neonatal pup brains were injected with ZIKV (100 PFU/
mouse) or medium at P1 and inspected at P10. Brain sections were
stained with antibodies for ZIKV (green) or the activated form of Cas-
pase3 (white). a: Hippocampus, b: Striatum, c: Thalamus, d: Hypothalamus,
e: Cerebellum. Scale bar = 200 μm (a-e). (PDF 194 kb)Additional file 3: Figure S2. Vaccination of female mice protects
offspring from early ZIKV infection. a. Schematic for immunizations and
mating of CD1 (ICR) female mice with ZIKV challenge in early pregnancy.
Mice vaccinated with E90 or PBS were mated at D28 and treated with
anti-Ifnar1 antibody at E5.5. Mice were infected with ZIKV virus (GZ01
strain) at E6.5. b. Viral loads in placenta at E16.5 were measured by qRT-
PCR. n = 16 for each group. All data are means ± SEM. Student’s t-test.
***p < 0.001. c. Condition of embryos in the PBS group after ZIKV infec-
tion at E18.5 (arrows indicate physical deformities, also shown in the left
lower image). Scale bar = 0.5 cm d. Newborn mice at P1 born to E90-
vaccinated mothers. Scale bar = 1 cm. (PDF 92 kb)
Additional file 4: Figure S3. E90 vaccination does not affect body
weight significantly. Body weights of vaccinated or control mice before
mating. Mock + Veh: n = 5, Mock + E90: n = 5. Data are means ± SEM.
Student’s t-test. ns: not significant. (PDF 70 kb)
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